CYIOS names new leadership, plans AI medical platform development

CYIOS Corporation (OTC: CYIO) announced that David Lewis stepped down from his roles with the company. As part of the transition, Lewis voluntarily returned 16,560 Series D Preferred Shares to CYIOS and canceled outstanding salary and loan obligations.

The company stated it is working with its independent auditor to complete two years of PCAOB-audited financial statements, with 2024 fully completed. CYIOS continues focusing on increasing working capital through strategic investment initiatives aimed at paying down debt obligations of its subsidiary Noir Medical Supplies, with completion expected by mid-2026.

"These are meaningful milestones in strengthening CYIOS' foundation for growth," said John O'Shea, Chairman and CEO of CYIOS Corporation. "We remain committed to disciplined financial management, profitable expansion, and delivering long-term value to our shareholders."

CYIOS announced plans to engage artificial intelligence and software-as-a-service advisors to develop CyioIQ, described as an AI-driven medical platform. The company stated this initiative aims to determine the platform's scope, architecture, design, business case, and build cost.

The implementation is intended to streamline operations within Noir Medical Supplies and potentially create new revenue streams through third-party distribution partnerships, according to the company's statement.

CYIOS Corporation operates as a diversified holding company focused on medical supplies, technology, and fintech sectors. Through subsidiary Noir Medical Supplies, the company maintains presence in the U.S. medical distribution sector.

You May Also Be Interested In

• Freedom Broker Upgrades Mondelez International (MDLZ) to Buy
• Prologis launches $5B at-the-market equity offering program
• AMTD Digital shifts fiscal year end from October to December